Back to dashboard
CommercialCoverageMedium impact

Genetic Testing for FMR1 Variants (including Fragile X Syndrome)

Blue Cross & Blue Shield of Mississippi·MS · Pediatrics, Neurology, OB-GYN +2 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply

Summary

BCBS MS updated their genetic testing policy for FMR1 variants (Fragile X syndrome testing). The policy defines when genetic testing for Fragile X is medically necessary versus investigational, affecting coverage determinations for developmental delay, autism spectrum disorder, and reproductive counseling cases.

Action Required

Action needed
Immediately: Review current Fragile X genetic testing claims to ensure they meet the medically necessary criteria outlined in the policy. Verify that testing requests are for approved indications: individuals with intellectual disability/developmental delay/autism, women under 40 with primary ovarian insufficiency, individuals with tremor/ataxia symptoms, or those with family history seeking reproductive counseling. Claims for other uses may be denied as investigational.